PPFIA1 and chronic myelogenous leukemia, BCR-ABL1 positive: Because KIT expression must be inhibited to enable apoptosis induced by BCR/ABL inhibitors in CML cells, our findings provide a rationale for therapeutic targeting of PPFIA1 levels to overcome aberrant phospho-KIT activity and induce significant anti-CML effects.